Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.


 


FIRST AMENDMENT


 


This First Amendment, effective as of the date
set forth above the signatures of the parties below, amends the Exclusive Patent License Agreement dated April 15, 2011 (the “LICENSE
AGREEMENT”) between the Massachusetts Institute of Technology, a Massachusetts corporation having its principal office at
77 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“M.I.T.”), and Enumeral Biomedical Corp., a Delaware corporation
having its principal place of business at 1450 Broadway, 24th Floor, New York, NY 10018 (“COMPANY”).


 


WHEREAS, M.I.T. and COMPANY wish to amend the
LICENSE AGREEMENT to clarify how equity issuances are to be made under the LICENSE AGREEMENT;


 


NOW, THEREFORE, in consideration of the promises
and mutual covenants contained herein, the parties hereby agree as follows:


 


		1.	Section 4.1(k) of the LICENSE AGREEMENT shall be deleted and replaced in its entirety with the following:





 


(k)          Equity.


 


(i)          Initial
Grant. COMPANY shall issue a total of * shares of Common Stock of COMPANY, $0.0001 par value per share, (the “Shares”)
to M.I.T., WHITEHEAD, HARVARD and HOSPITAL, collectively the “Shareholders”), in the amounts as M.I.T. shall direct.
Such issuances shall be recorded on the Stock Transfer Ledger of COMPANY on the EFFECTIVE DATE and the Shares shall be delivered
to the Shareholders within thirty (30) days of the EFFECTIVE DATE.


 


COMPANY represents to M.I.T. that, as of
the EFFECTIVE DATE, the aggregate number of Shares equals * of the COMPANY’s issued and outstanding Common Stock calculated
on a “Fully Diluted Basis.” For purposes of this Section 4.1(k), “Fully Diluted Basis” shall mean the total
number of issued and outstanding shares of the COMPANY’s Common Stock calculated to include conversion of all issued and
outstanding securities convertible into Common Stock, the exercise of all outstanding options and warrants to purchase shares of
Common Stock, whether or not then exercisable, and the conversion or exercise of all rights to purchase or acquire Common Stock,
whether or not then convertible or exercisable. Notwithstanding the foregoing, for purposes of calculating the COMPANY’s
issued and outstanding Fully Diluted Common Stock, all Convertible Notes issued prior to the close of the COMPANY’s initial
equity financing shall be excluded until the date of their conversion, at which time sufficient shares will be issued by COMPANY
to the Shareholders to maintain their aggregate ownership at * as described in this Section.


 




    	Page 1 of 5



    	 



    

 


(ii)         Anti-Dilution
Protection Through Funding Threshold. COMPANY from time to time shall issue additional shares of Common Stock to the Shareholders,
pro rata in accordance with their respective ownership of the Shares, as may be necessary to ensure that the Shares (together with
any and all shares issued pursuant to this Section 4.1(k)(ii)) continue to represent in the aggregate at least * of the COMPANY’s
issued and outstanding Common Stock calculated on a Fully Diluted Basis, as calculated after giving effect to the anti-dilutive
issuance. Such issuances shall continue until and including the date upon which a total of * in cash in exchange for COMPANY’s
capital stock (the “Funding Threshold”) shall be received by COMPANY. Thereafter, no additional shares shall be due
to the Stockholders pursuant to this section.


 


(iii)        Participation
in Private Equity Offerings After Funding Threshold. After the date of the Funding Threshold, each of the Shareholders shall
have the right to purchase additional shares of COMPANY’s capital stock in any private offering by the COMPANY of such capital
stock in exchange for cash (“OFFERING”), to maintain its pro rata ownership as calculated immediately prior to such
offering on a Fully Diluted Basis, pursuant to the terms and conditions at least as favorable as those granted to the other offerees.
All rights granted to the Shareholders pursuant to this Section 4.1(k)(iii) shall terminate immediately (i) prior to a firm commitment
underwritten public offering of the COMPANY’s common stock resulting in gross proceeds to the COMPANY of at least $10 million.
This right granted to the Shareholders shall not apply to any equity issued to any lender, the issuance of any shares in connection
with the conversion of any equity securities, the issuance of securities to a collaboration partner or joint venture, or the issuance
of any securities under any equity incentive plan.


 


(iv)        Adjustments
for Punitive Round Financings. After the date of the Funding Threshold (the “Funding Threshold Date”), if COMPANY
takes any action that is a Dilutive Issuance (as defined below), then immediately following such Dilutive Issuance, COMPANY shall
issue to the Shareholders additional shares of Common Stock such that the Institution Share Number (as defined below) equals the
product obtained by multiplying the Institution Share Number in effect immediately before the Dilutive Issuance by the Adjustment
Fraction defined below. The Institution Share Price in effect immediately after the Dilutive Issuance shall be adjusted to equal
the result obtained by dividing the Institution Share Price in effect immediately before the Dilutive Issuance by the Adjustment
Fraction defined below.


 


	Adjustment Fraction equals:	(A + C)
	 	(A + B)


 


where:


 


A = the number of shares of Common Stock issued
and outstanding on a Fully Diluted Basis immediately prior to the Dilutive Issuance


 


B = the number of shares of Common Stock that
could be purchased at the Institution Share Price immediately prior to the Dilutive Issuance using the aggregate consideration
received by COMPANY in connection with the Dilutive Issuance.


 


For purposes of calculation of “B”,
if the Dilutive Issuance is as described in subpart (III) of the definition of Dilutive Issuance below, the aggregate consideration
received by COMPANY shall be the price per share at the applicable Convertible Instrument (as defined below) immediately following
the Dilutive Issuance (as adjusted for the Dilutive Issuance pursuant to the terms and conditions of the Convertible Instrument
or the COMPANY’s Certificate of Incorporation or other applicable formation document) multiplied by the total number of shares
of Capital Stock (as defined below) into which such newly adjusted Convertible Instrument could be exercised or converted, whether
or not then exercisable or convertible.


 




    	Page 2 of 5



    	 



    

 


C = the number of shares of Capital Stock issued
on a Fully Diluted Basis pursuant to the Dilutive Issuance, or, if a Convertible Instrument is issued in the Dilutive Issuance,
the number of shares of Capital Stock issuable on a Fully Diluted Basis if all shares of the Convertible Instrument were converted
into the applicable Capital Stock, whether or not then exercisable or convertible.


 


For purposes of calculation of “C”,
if the Dilutive Issuance is as described in subpart (III) of the definition of Dilutive Issuance below, then C shall be the total
number of shares of Capital Stock into which the newly adjusted Convertible Instrument could be exercised or converted, whether
or not then exercisable or convertible.


 


The following definitions shall apply to this
Section 4.1(k)(iv):


 


“Capital Stock” shall mean any form
of COMPANY’s capital stock.


 


“Convertible Instrument” shall mean
any instrument issued by COMPANY that is convertible into, or may be exercised in exchange for, any Capital Stock.


 


“Dilutive Issuance” shall mean any
issuance of Capital Stock or any Convertible Instrument by COMPANY where such issuance results in (I) the price per share of COMPANY’s
Common Stock being reduced to less than the current Institution Share Price (as defined in this subsection), (II) the price per
share of any Convertible Instrument being reduced to less than the price of the same series or type of Convertible Instrument in
the most recently preceding offering and sale of such Convertible Instrument, or (III) the conversion ratio of any Convertible
Instrument changing such that each previously issued share of such Convertible Instrument becomes convertible into a greater number
of shares of the applicable Capital Stock.


 


“Institution Share Number” shall
mean the number of shares of COMPANY’s Common Stock that the Shareholders own on the date of the Dilutive Issuance, as adjusted
from time to time pursuant to this section. Notwithstanding the foregoing, any shares of Common Stock acquired by the Shareholders
pursuant to Section 4.1(k)(iii) shall not be included in the Institution Share Number.


 


“Institution Share Price” shall
mean the value per share of the shares of Common Stock included in the Institution Share Number, as adjusted from time to time
pursuant to this section. For purposes of this section, the initial Institution Share Price to be used in an adjustment resulting
from the first Dilutive Issuance to occur after the Funding Threshold Date shall be the Fair Market Value per share of the Common
Stock of the COMPANY effective on the Funding Threshold Date.


 




    	Page 3 of 5



    	 



    

 


“Fair Market Value” of a share of
Common Stock shall be the highest price per share that the COMPANY could obtain from a willing buyer (not a current employee or
director) for shares of Common Stock sold by the COMPANY, from authorized but unissued shares, as determined in good faith by the
Board of Directors of the COMPANY, unless the COMPANY shall become subject to a merger, acquisition or other consolidation pursuant
to which the COMPANY is not the surviving party, in which case the current fair market value of a share of Common Stock shall be
deemed to be the value received by the holders of the COMPANY’s Common Stock for each share of Common Stock pursuant to the
COMPANY’s acquisition.


 


(v)         Massachusetts
General Hospital. If HOSPITAL’s ownership of HOSPITAL’s shares shall at any time create a conflict of interest
affecting HOSPITAL’s ability to conduct clinical trials, clinical studies, clinical research or clinical validation or if
HOSPITAL shall otherwise be required to divest itself of HOSPITAL’s shares due to law or HOSPITAL’s conflict of interest
policies, then HOSPITAL shall have the right to elect to sell (“TRANSFER”) the HOSPITAL’s shares to any third
party (“PROPOSED TRANSFEREE”) free of any restriction and free of any co-sale rights, tag along rights, of COMPANY
or its stockholders or investors provided however the HOSPITAL shall not transfer the HOSPITAL’s shares to a COMPETING ORGANIZATION
or to an investor in any COMPETING ORGANIZATION. Such third party investor shall agree to execute any and all investment documents
binding on the HOSPITAL. Notwithstanding the foregoing, the COMPANY first and then the other stockholders of the COMPANY shall
have the right of first refusal to purchase such shares at the price offered to such third party by the HOSPITAL pursuant to the
following conditions. HOSPITAL shall first offer to sell to the COMPANY or any Persons designated by the Company as the “Purchaser”
hereunder (the COMPANY or such designees being referred to as the “DESIGNATED PURCHASER”) the HOSPITAL’s shares
that the HOSPITAL desires to sell (the “OFFERED SECURITIES”), at the same price and on the terms identical in all material
respects to those terms that the HOSPITAL intends to sell the Offered Securities to the PROPOSED TRANSFEREE; provided that the
DESIGNATED PURCHASER shall have no right to acquire the OFFERED SECURITIES unless the DESIGNATED PURCHASER acquires all of the
OFFERED SECURITIES. If such proposed TRANSFER involves consideration other than cash, any Person having rights under this subparagraph
(v) shall have the right to elect to pay, in lieu of such non-cash consideration, cash in an amount equal to the fair market value
of such non-cash consideration. Such offer shall be made by a written notice (the “NOTICE of PROPOSED TRANSFER”) delivered
to the COMPANY not less than thirty (30) days prior to the PROPOSED TRANSFER. Such NOTICE of PROPOSED TRANSFER shall set forth
the identity of the PROPOSED TRANSFEREE, the OFFERED SECURITIES proposed to be sold, the terms and conditions of the proposed sale,
including price per share and any other material terms and conditions or material facts relating to the proposed sale. In addition,
the HOSPITAL shall provide to the DESIGNATED PURCHASER all such other information relating to the OFFERED SECURITIES, the PROPOSED
TRANSFEREE and the proposed sale as the DESIGNATED PURCHASER may reasonably request. If the DESIGNATED PURCHASER does not accept
the HOSPITAL’s offer with respect to all of the OFFERED SECURITIES within fifteen (15) days after receipt of the NOTICE of
PROPOSED TRANSFER from HOSPITAL, the HOSPITAL shall have the right for a period of sixty (60) days following the sixtieth day after
the COMPANY received the NOTICE of PROPOSED TRANSFER from the HOSPITAL, to sell all of the OFFERED SECURITIES, but at not less
than the price, and upon terms not more favorable to the PROPOSED TRANSFEREE, than were contained in the NOTICE OF PROPOSED TRANSFER.
If the OFFERED SECURITIES are not sold within such 60-day period, such OFFERED SECURITIES shall continue to be subject to the requirements
of this subparagraph (v).


 




    	Page 4 of 5



    	 



    

 


(vi)        Miscellaneous.
The Shares, and all other shares of Common Stock and other securities of the COMPANY that may be issued to the Shareholders pursuant
to this Section 4.1(k), shall be duly authorized, validly issued, fully paid and nonassessable.


 


2.          Section
14.1 of the LICENSE AGREEMENT shall be amended to provide the following notices information for M.I.T., for all matters relating
to the LICENSE AGREEMENT, including equity and any equity actions after the initial issuance of shares:


 


	If to M.I.T.:	Massachusetts Institute of Technology
	 	Technology Licensing Office, Room NE18-501
	 	One Cambridge Center, Kendall Square
	 	Cambridge, MA 02142-1601
	 	Attention: Director
	 	Tel: 617-253-6966
	 	Fax: 617-258-6790


 


3.          Except
as specifically modified or amended hereby, all other terms and conditions of the LICENSE AGREEMENT shall remain unchanged and
in full force and effect. Capitalized terms used herein and not defined shall have the meanings set forth in the LICENSE AGREEMENT.


 


IN WITNESS WHEREOF, the parties have caused
this First Amendment to be executed under seal by their duly authorized representatives.


 


The Effective Date of this First Amendment is March 8, 2013


 


	MASSACHUSETTS INSTITUTE OF

TECHNOLOGY	ENUMERAL BIOMEDICAL CORP.
	 	 
	By: /s/ Lita L. Nelsen	By: /s/ Arthur H. Tinkelenberg
	 	 
	Name: Lita L. Nelsen	Name: Arthur H. Tinkelenberg
	 	 
	Title: Director Technology Licensing Office	Title: President & CEO


 



    	Page 5 of 5